PT  - JOURNAL ARTICLE
AU  - Suthar, Mehul S.
AU  - Zimmerman, Matthew G.
AU  - Kauffman, Robert C.
AU  - Mantus, Grace
AU  - Linderman, Susanne L.
AU  - Vanderheiden, Abigail
AU  - Nyhoff, Lindsay
AU  - Davis, Carl
AU  - Adekunle, Seyi
AU  - Affer, Maurizio
AU  - Sherman, Melanie
AU  - Reynolds, Stacian
AU  - Verkerke, Hans P.
AU  - Alter, David N.
AU  - Guarner, Jeannette
AU  - Bryksin, Janetta
AU  - Horwath, Michael
AU  - Arthur, Connie M.
AU  - Saakadze, Natia
AU  - Smith, Geoffrey Hughes
AU  - Edupuganti, Srilatha
AU  - Scherer, Erin M.
AU  - Hellmeister, Kieffer
AU  - Cheng, Andrew
AU  - Morales, Juliet A.
AU  - Neish, Andrew S.
AU  - Stowell, Sean R.
AU  - Frank, Filipp
AU  - Ortlund, Eric
AU  - Anderson, Evan
AU  - Menachery, Vineet D.
AU  - Rouphael, Nadine
AU  - Mehta, Aneesh
AU  - Stephens, David S.
AU  - Ahmed, Rafi
AU  - Roback, John D.
AU  - Wrammert, Jens
TI  - Rapid generation of neutralizing antibody responses in COVID-19 patients
AID  - 10.1101/2020.05.03.20084442
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.03.20084442
4099  - http://medrxiv.org/content/early/2020/05/08/2020.05.03.20084442.short
4100  - http://medrxiv.org/content/early/2020/05/08/2020.05.03.20084442.full
AB  - SARS-CoV-2 is currently causing a devastating pandemic and there is a pressing need to understand the dynamics, specificity, and neutralizing potency of the humoral immune response during acute infection. Herein, we report the dynamics of antibody responses to the receptor-binding domain (RBD) of the spike protein and virus neutralization activity in 44 COVID-19 patients. RBD-specific IgG responses were detectable in all patients 6 days after PCR confirmation. Using a clinical isolate of SARS-CoV-2, neutralizing antibody titers were also detectable in all patients 6 days after PCR confirmation. The magnitude of RBD-specific IgG binding titers correlated strongly with viral neutralization. In a clinical setting, the initial analysis of the dynamics of RBD-specific IgG titers was corroborated in a larger cohort of PCR-confirmed patients (n=231). These findings have important implications for our understanding of protective immunity against SARS-CoV-2, the use of immune plasma as a therapy, and the development of much-needed vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded in part by an Emory EVPHA Synergy Fund award (M.S.S and J.W), and by the National Institutes of Health NIAID Infectious Diseases Clinical Research Consortium (IDCRC) UM1 AI148684 (D.S.S, R.A and J.W), R01 AI137127 (J.W), ORIP/OD P51OD011132 (M.S.S), R00 AG049092 (V.D.M) and World Reference Center for Emerging Viruses and Arboviruses R24 AI120942 (V.D.M), and HIPC 5U19AI090023-10 (N.R, E.A and A.M) and VTEU 1UM1AI148576-01 (E.A and N.R). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the authors on reasonable request, see author contributions for specific data sets.